ARENARRAS REPRE Sy 7937 B01 CQ: SGLTZIERILEA LICE REFS? | Empoglifosin, Cardiovacular Outcomes, and Morea in Type 2 Diabetes eRe: 2o21eSAI2481 FORE: HERB SK RMGROEL AP IL QU — {sence cusesay oan oan tee Zour GP Syntet ian OY epsom ssinpes! ARRORER, MCRAE RUDP-ZE—P, HMMS LSAEBRENS HTH, [EDLEFDAEFMLTEVANS) CERMAK, PERICSGUT MMOL AT YT y DLE ERATE. [ascyonw 2BHTIMACEDOAS - WBE HIE 7) EUSERT. UEETOORENCEROST. BemEMoiNesSDNs F. Fh LOBAL LORLMS FRANOWITAT. 90, D354 ey pmaTetAEN, EGMI— FE ay JeFO TELNET MEAD) (-OSBRTSCLZOBRORBIE (RCT) = ROLE. WREAAEACEMPEDSRE LTH, IntroductionBES SATHRAORL roam KOM pais eI CLE CHA RRA DUT AY DCTS A THA RRS FOICORIRT 40 CRETE 2EAIRATI. Bo tek SIRRRAE TUR UsdPeUKPOS:-C12, mssUesEARL Menenesran sr ASwREIMS RAM eIC IRs mes Rima repumeiouKeosa cia bu SS CHM. ARR EMS tar, BES SATHARORD 2008¢F IceRoRCTARLT. FRBOR CU Arec amen A aS tire ate AccOND aD LAD MERE A DBIZROMEC DB TLEPSEAET, WG WD" SU RST FIBE IEE SKA, CMEFECR ATE G5 novice AIMED tema oiee nome eeeshee, SUA ATC FFSe REC Ha9;A, DEMISE (5 weenNEG oi hima ick? ~EREOMEOSC, SSE AR CIAL BRCUBII57%, OORATS.Son7% (25%) OROMRERABE, CT? CSTR BS SATA COROAMRASC, HomIcEREROMIC )D—TRRE HG 20108 DEAE b (neat 2010375482), Aamir PBMC TONe- ROTTS LORS ORL + 20128081 =I7R— b am Geri Soe 2012601215) AEROMONAS, FRO DAWICE, M4 VAD HES + NSTALCT SM FEET E. Bie FSR, mmeeRAS MORIA, FEMS CMS ‘CMS IS (BM SMDeCHMCES) OMRON (AMMO) eat RCRLMSS. OUSMASTMESHS Clinical Question IA UZDBEENRICLT (Seca can ROMET Shea ARERUUP TURD T) RNA ROTEL T (SANE EPR AS HoALe7 SLL F REPS) AS OMRscAMERE LB LIES (sGUr2ii255-SHoardEe F9-7A> RMD EU SABIE Tat < SGUABE I-A AD HARD ELS clas effecre MELT) MEAD MOPED RICA EE LIEU) |Methods Setting sABWT 400M ADY—=VIU SOHESDYS 700A SABHA NBR ADI—RVIORBS, ProvocoiBHH PST NABOsooeie sd. GOLF AD AREAS CES AME CHIR TE BPRS - BEV Z Hid Protocoll MIDST. BREA CURED SSBANTUS (iE) + BBAUANPSLATIE RT YDS + HRCA UV H—OBRASSBAD TS, Inclusion criteria LR 1ARRLLE, AMIASECF, eGFRIOGLE mn Faiotee emer 0am o-cHDALEHS7.0.100 Dine RBE DELLS OIE, 22ALa HMRSIAE (souuLLRS, AoarmRcE Mines oso, ans) RURAL EAT Exclusion criteria an CRB ef t SWAN RLRey 6 FMRSD. mame AMER WT SNDeRE. LTC HME abe pocrtawe <3) ssrA Mea, coat Bes Sole TAS AS, CREPE SSunoseaa@ emRORe. TAI ABR umes ome inoacamncesenm SH 9 SusFT, BERRA RENAN oMmCRONSTVEL Mime, Me HEAL eM mceCRA ae WMSMERSTEUTUE, ARE RRLRandomization and masking SBR Pot bO-JLorct nin eros DMG, A REMEE LETS SONOS BAMERANDARIPERHANT, FIOM: L/omg: LV sag 1 SL: PSST ANN Modified ITA RAO ARETE ADAP RRRIRICINATE Khun SARIN ES COMBE, RENT SORONARD BHC CAM SAMS 1 BMEROAOMN TUS eazameLN. PIAL HY SE OMB ERATED, Sot endpoint RBIBINT A211 Intervention Intervention2# —_...Empagliflozin10mg EmpagliflozinaSmg Controle Placebo MAO WATA EDODMEVATRFONACMLTSLS WRF LPS OSE Hiner + ADORE + MBAMEETELS, Local GUO TA XR - BORE + Ee6, ERUEEET TADEA BNOWASN—ABR PG240L1 F 9 — Zia ROB TOT KE (Po teAere, ns - sub >sbERIPcvOHEA SINE) XESHRLEEM ens, A ASRORE + PbS aIHE HAR CHEM BERT UPS ERAN INS» SuDshuEYDAURRR ODL > EBSA S TIES) TAD wiastikis. Local guidelinelc#EDT AROMAS CEBU 24952009 DH1-1 RST Fama? 0H + BEY 8x WH SAry7 2 csuiammeeor SAF YFSCHMET AVY + REBAR ARBELT mobev.1isn DT StAME CSU + Ns « T2007 eH TVARETISTZO + INS + SUNEML L7 SAME ESPrimary Outcome 3 -polnt MACE (majo adverse cardiovascular events] DMM ESF + FEBS EH LARS + IEBOT MEZA Slew ie TMM SFE DIE ‘supplementary append secton &) catenin ons ROAM COMBREELTHDD NETS? + Sudden “cardiac death" DREAMED REE, DILL ORAoATsrEAL [CERRORMROMELE) SOMAMRID TS YS Secondary key outcomes primary outcomes +7SETEBLDTE CARE. (soft endpoint) Additional secondary cardiovascular endpoints + Silent Ml. Heart fallre requiring hospitalization + New onset albuminuria/ New onset macroalourinuria + Composite microvascular outcome HUAI Feat - SFR, eorneas Tertiary Further cardiovascular endpoints + ll cause mortaity + Cv deat (including ata stroke and ft Mt + nonftaiMl, nonfatal stoke, TA + coronary revseularizatin procedures + Hospitalization for unstable angina Safety MedDRd etsy sce) CES DPOF ‘or aaOINEED PaeRC MINN Stanement ons em.cewaneenoescac none UAGlARIn BAD iNT? > PENARURR CMR SER EMENL, BELORBT ETRY S SEE (iE C1 MERRY S PION, BACRIHAEL CSS FRE: MITEL ‘Adverse events of special interest inieiarone/a eames SRI bn) bea GERM HPS SAU RSnE, SORBR Voune depeien, EEE, EERIE, SF Statistical analysis wn LLY IND omg 25092, FIM SHB OT /womg 79, TV UsnT ICAO RMT aus tncorrememen aso. REStatistical analysis smetone: 1. Four-step hlerarchicabtesting strategy. ses cacti: 2, Seco bineane Ram CAMMIRE cp coon Statistical analysis rematss PEELS 21a, MON fitio (eeY oe) EEOC, RNAI. WME AS HEE ime Seema MiRAREOHS MER LIS, HST OL some oc SRIIL-7. wat, a, con ORNATE EnSKamissiamcs2eeeeraLn RINREEONEIS, ISS eM CR UASeEOMANI, RMAERD IOS hiner AEC anne, aenoRRoAES MmomNRE, SIIN~TWH, RENORL Ceres NEIMELT, MethodD& Hs SRERORTC, FH SEMORE Ronin DRA is, BED) 1 UATBEA DMEM LIENS PPA (MERAY *SU=INS - TOD EAAIETS AR Empaglflozin1ong + 25mg F SteAELLA R= ADSU NS» LOHR S SRM EHTS PO bys Le CoM PETE EASCVO[MI+Stroke) AME SC IEC CIRO TER URSA SHS SMELL, ERRANDResults wm ae ee ine 2 o Borst 2 2 aoe UBER EH 23K mga 1079 roa 25mg aoe “20.3% 23.7% 236 fue ise ne ik? masa 74 53 22 fr OS 3 ° Fownmowsts, mates, emmeMTACE TH? Faun pe ndesngs SSC NMERRCRLTC Dewees ss0- ne TeoeMouMNaN eS RAST OF feM63M@, BMIZ0E5 HbALC 820.85. ISAT. E25% + LOMBLESTI6 Bik: MI46%6 - SRIEA6% - CABG? ‘Stroken3% = PADIOK = BION. (47 MEEL35.117775210mmiig, LDLBS, GR? 870% BAI, PUP21% BASE, KAD ita, k20%, PEP196, FUR BG74% - oppaiiss. INS4B% (52a) sU42% -TZDAK M20% 4 2S 0 79%, MENARD MRFEROS%6 (acr/anaso | 965 FIIR43 » MRAGS) BOF, PRES ADIY IETE RIOR HVKABK.ote Enge 10m9+2506 sear oma 2.6 1.024) 2.62054) © oan a 3.1 22s) 3.2e236) & ewes, ae f i seein - 1 i oe [ese | ame | ae | wT aE aera 15.4 = ee} ae] 11.0 or ep | 130 ere} a r ie freer 9ssere] mere r [orcas r rm ms aa Dine s SDI ASCVDMIE “AML Stoke ~0.9¥ 50.6% OFRRC 0.8% 31 0.2% RAH widen + other =4.0% 38 2.7% enemies _ Fue = SS OMEPS KAO TID ee Z34UPObHh Sweameno suet ae aa a Sani Becititise 39 30 34 Sasnawomasinuees oom sa an as sme wane shaimea7zenes< SRoMTEResH rmmman no 66 75 “Sete. Ses: CERAM CHRIS oman anne 28 Smemicenns ommmels Tarimemoreo responce 2o1ur ohhh iverrgerpea seas BRICU. Hon ABC RIND, mB pemccees RATE. AMEN CrbaiciARIaIeL Bnomicomeris recut APSURHT CLS, SHAD OMI RTSTUCRICRIENN Lousieze? |; svameerr os EReosRULMOE “29 eR CHECILIME FROMM.) (31 5%8118.5%) ACSNORT LAUT. U, FPUSS OTST BD) 1 ZSwNeeis, See. OMETEPOTSEREL SERA Soo umwbicmmIcenen 6 ofS «INS SU TZD gam Te Me 2G BWA je) Se eS Pood 731760 497 BHEUZ IRF ORES FoeORRCIRAIRR “MRA, CORP, 7REU> - WHBnaneey t Zorenercis RE eka (coaR PORT, Eh (CH SRAARIE) CPUS OMNRA THE ‘Table 2 ‘Adverse Event soeitre) anima ra Rene aneucen eve ‘Eoaleautre meeshen amen See wane mae pease ces. Table S23. REO zyercis iaisiowerre Siemon cue, mom oma fhe waza imam es > mane? worneute, Eomasacieeserusememe un oenien BAB SORAIGBOAS GIKUNSH iwoRS c, IBD 2 (BIOGAS MISA) NE, REL TOR FN TUR SIRE MBL